2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Young Adult
PAPER

3282 Socioeconomic disadvantage is associated with worse event-free survival and higher relapse rates in adolescents and younger adults with acute lymphoblastic leukemia treated with pediatric-inspired regimens

Melanie Wendy Castro Mollo, MD, Julia Keating, M.S.2, Joseph Brennan deBettencourt, MD3, Yael Flamand, MS4, Jacqueline S. Garcia, MD5, Eric Stephen Winer, MD6, Hari S. Raman, MD, MBA7, Jonathan D. Paolino, MD8, Yannis K. Valtis I, MD9, Martha Wadleigh, MD10, Kira Bona, MD, MPH11, Lynda M. Vrooman, MD12, Andrew E. Place, MD, PhD13, Stephen E. Sallan, MD14, Lewis B. Silverman, MD15, Richard Stone, MD16, Daniel J DeAngelo, MD, PhD17, Andrew Hantel, MD, MPH18, Marlise Rachael Luskin, MD, MSCE19, Shai Shimony, MD, MPH20
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Instituto Nacional De Enfermedades Neoplasicas, Lima, Lima, Peru
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
9 Memorial Sloan Kettering Cancer Institute, New York, New York, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute & Boston Children’s Hospital, Boston, Massachusetts, United States
15 Columbia University Irving Medical Center, New York, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Outcomes for adolescents and younger adults (AYA) with newly diagnosed acute lymphoblastic leukemia (ALL) have improved, but significant and persistent patient-specific differences in outcomes remain, even after accounting for known disease risk factors. Socioeconomic disadvantage may contribute to these differences. We assessed the impact of area-level socioeconomic disadvantage on relapse, event free survival (EFS), and overall survival (OS) in AYA ALL patients treated at 12 Dana-Farber Cancer Institute (DFCI) Consortium sites across United States over two decades.

Methods: We conducted a retrospective cohort study of patients 15-50 years old with B- or T-ALL who received front-line chemotherapy with a DFCI consortium pediatric regimen between 2001 and 2025. Socioeconomic status was measured by the national Area Deprivation Index (nADI), a composite measure of neighborhood-level socioeconomic disadvantage derived from U.S. Census data. nADI is a normalized index ranging from 1 to 100, indicating least to most disadvantaged neighborhoods. Home address was geocoded and linked to an nADI score, which was analyzed both as a continuous and binary (high >25 or low ≤25 deprivation, based on the approximate median score in New England). All time-to-event outcomes were measured from time of diagnosis. OS was defined as time from registration/first treatment until death or last follow-up. EFS was defined from registration/first treatment until relapse, death, or last follow-up. OS and EFS were estimated by Kaplan-Meier method and compared by log-rank test; cumulative incidence of relapse (CIR) and non-relapse mortality were estimated using competing risks methods and compared by Gray's test. Cox models assessed univariable associations; multivariable models were built by backward stepwise AIC selection among age, sex, race/ethnicity, BMI, WBC at diagnosis, and binary nADI.

Results: Among 384 patients, the median age was 24 years (66% were aged 15-29), 71% (n=272) had B-ALL, and the median follow-up was 6.4 years (95% CI: 5.7-6.8). The median nADI was 22 (IQR 11-38); 44% lived in high nADI neighborhoods (nADI>25). Patients with high neighborhood deprivation (nADI > 25 vs. ≤ 25) were more likely to be aged 30-50 vs 18-29 years (41% vs 28%, p=0.009), Hispanic vs non-Hispanic (26% vs 14%, p=0.02), insured by Medicaid/Medicare vs other insurance (25% vs 11%, p=0.005).

The 5-year EFS and OS for the entire group were 66% and 78%, respectively. Patients with high nADI had lower 5-year EFS (59% vs 71%, p=0.01), higher 5-year CIR (30% vs 19%, p=0.01), higher rates of allogeneic stem cell transplantation (37% vs 22%, p=0.001) and lower 5-year OS (75% vs. 80%), though OS difference did not reach statistical significance (p=0.08).

On univariable analysis for EFS, each 10-unit increase in nADI was associated with an 8% increase in the hazard of an event (HR 1.08, 95% CI 1–1.18, p=0.049). Similarly, each 10-unit increase in nADI was associated with 12% increase in risk of relapse (Subdistribution Hazard Ratio 1.12, 95% CI 1.03-1.23, p=0.01). When evaluated as a binary variable, high nADI patients had significantly higher risk of an event (HR 1.56, 95% CI 1.1–2.2, p=0.01) along with a trend toward higher risk of death (HR 1.46, 95% CI 0.95–2.24, p=0.08); age, BMI (obese/overweight), and insurance status were also significant predictors of both outcomes.

On multivariable analysis, high nADI was associated with worse EFS (HR 1.44, 95% CI 1.00–2.08, p=0.050). In addition, older age at diagnosis (HR 1.03 per year, 95% CI 1.01–1.04, p=0.008) and diagnostic WBC ≥30k (HR 2.42, 95% CI 1.68–3.48, p<0.001) were found to be significantly associated with worse EFS.

Conclusion: Among AYA ALL patients treated at academic centers with a pediatric regimen, neighborhood-level socioeconomic status, as measured by nADI is associated with worse EFS, higher CIR and a trend towards worse OS. A practical measure of socioeconomic status, the nADI, aides in identifying patients at higher risk for relapse and should be used in prospective studies to identify opportunities to modify outcomes for this high-risk population.  

Melanie Wendy Castro Mollo, MD: No relevant conflicts of interest to declare.